RARE DISEASES MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES
Author(s)
Tarik Čatić, PhD, Health Economics and Pharmacoeconomics, Sarajevo, Bosnia; Rok Hren, PhD, MSc, Institute of Mathematics, Physics and Mechanics, Ljubljana, Slovenia; John Yfantopoulos, PhD, University of Athens, Athens, Greece; Olha Zaliska, PhD, DSci (Pharm), Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Presentation Documents
Rare disease Multi-Criteria Decision Analysis (MCDA) inter- dependence of the following criteria will be explored: efficacy, budget impact, safety, unmet need, strategic, patient preference, equity and severity. Introduction to each criteria will be provided to the audience. Scoring comparison between different countries will be performed. Presenters will demonstrate Rare Disease MCDA criteria transferability and application across European countries. Audience engagement is anticipated during the meeting.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Code
F5
Topic
Health Technology Assessment, Specific Diseases & Conditions